Compare FTLF & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | TMCI |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 120.4M |
| IPO Year | 2006 | 2021 |
| Metric | FTLF | TMCI |
|---|---|---|
| Price | $9.31 | $1.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.50 | $4.77 |
| AVG Volume (30 Days) | 37.0K | ★ 860.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | $21,744,000.00 | ★ $212,690,000.00 |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | $8.18 |
| P/E Ratio | $14.91 | ★ N/A |
| Revenue Growth | ★ 11.52 | 1.59 |
| 52 Week Low | $8.67 | $1.17 |
| 52 Week High | $20.98 | $7.78 |
| Indicator | FTLF | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 50.09 |
| Support Level | $8.67 | $1.24 |
| Resistance Level | $15.34 | $2.25 |
| Average True Range (ATR) | 0.57 | 0.21 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 45.45 | 32.50 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.